An observational study in Crohn Disease, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 3 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Massachusetts General Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Crohn Disease by Massachusetts General Hospital — 7 open to participants now, 8 under way, none of them phase 3. Crohn Disease · Massachusetts General Hospital.
Among the 14 studies in Crohn Disease by Massachusetts General Hospital, this one is one of 2 that started in 2019, is one of 5 observational ones, and was the 8th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →7 of the 14 studies in Crohn Disease by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 14+ · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18–75 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 14+ · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18–99
Massachusetts General Hospital · Sites in United States
Ages 18–75 · Healthy volunteers
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 3 Years to 20 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is below the median of 184 across 646 observational studies indexed under Crohn Disease.
Median enrollment 31 across the 9 interventional studies, 50 across the 5 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
4 of the studies in Crohn Disease by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04508088Massachusetts General HospitalSkeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease | 2026-12 |
| NCT04565821Massachusetts General HospitalFeasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe | 2027-04-30 |
| NCT07033208Massachusetts General HospitalFeasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance | 2027-04-30 |
| NCT05332639Massachusetts General HospitalPersonalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 14 studies in Crohn Disease by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to generate novel minimally-invasive serum protein signatures and biomarkers in children and adolescents with Crohn's Disease (CD) that correlate with and can predict and monitor patients who will have a prolonged response to Infliximab so that personalized medicine can be applied to patients with CD.
Prospective, observational study will enroll 120 unique pediatric Crohn's disease patients between the ages of 3-20 years among multiple sites. Patients will be naïve to TNF inhibitor. If patient is going to start infliximab or infliximab biosimilar, patient may be enrolled in study. Study length will be from commencement of infliximab until the infusion visit given at least 1 year after initiation. During the study, if the patient fails infliximab or biosimilar, they will be complete study once failure is indicated and discontinued on infliximab or biosimilar. Patients may be on concurrent IBD therapy such as antibiotics, mesalamines, immunomodulators and may continue in study if non-standard induction schedule or changes made during induction or maintenance to dose or frequency. Excluded patients will be those receiving infliximab or biosimilar infusions at home due to need for blood collection at time of infusion, on systemic corticosteroids (topical preparations such as budesonide are allowed), and those who have already undergone significant bowel surgery relating to their Crohn's.
Study visits will take place in conjunction with previously scheduled routine clinic visits or infusion visits. At initial study visit, demographics, medical and surgical history, PARIS classification, PCDAI, weight and height, fecal calprotectin, labs, EGD and colonoscopy report and pathology report, cross-sectional imaging reports and concurrent medications will be obtained and entered. Parameters measured at each study visit will include any obtained labs, weight and height, PARIS classification, PCDAI, infliximab dose (mg/kg) and dose interval. There will be four study visits throughout the course of 1 year after initiating infliximab. At these four visits, blood will be obtained in PAXgene tubes for RNA analysis and serum for banking for SOMAscan analysis.
Patients 3-20 years old diagnosed with Crohn's Disease starting infliximab
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Blood collection
Define pretreatment serum protein biomarkers that predict and monitor response to TNF inhibitors (Discovery Cohort)
Run 120 pediatric Crohn's patients' serum at baseline, week 14, and week 54 on SOMAscan; Develop predictor model for protein biomarkers that predict response from baseline serum
Time frame: 2 years
Identify pathophysiological mechanisms associated with response or lack of response in patients receiving IFX using SOMAscan.
Identify pathophysiological mechanisms associated with response or lack of response in patients receiving IFX using SOMAscan.
Time frame: 2 years
Use systems biology to map out pathways activated in those patients at week 14 that have clinical and laboratory response to infliximab
Use systems biology to map out pathways activated in those patients at week 14 that have clinical and laboratory response to infliximab
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2019 to primary completion in Sep 2024, 58 months.
Of 232 non-industry observational studies under Crohn Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 101. This study's 58 months is above that.
Counting every sponsor, half of 305 studies reached it within 41 months; a quarter within 29 and three quarters within 88.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Nov 2022 → Sep 2024 and completion Jan 2023 → Nov 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →